May 01, 2025 04:38 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
India shuts airspace for all Pakistani flights days after Pahalgam massacre | Bangladesh Supreme Court stays HC order granting bail to Chinmoy Krishna Das in sedition case | After Pahalgam terror attack, India warns Pakistan over 'unprovoked firing' along LoC: Report | PM Modi to skip Russia's Victory Day parade on May 9 in backdrop of Pahalgam attack | PM Modi holds top cabinet meetings amid India's wait for Pahalgam terror attack revenge | Fire in Kolkata hotel kills 14, police constitute SIT; local administration faces heat over 'negligence' | India will attack us in next 24-36 hours, claims Pakistan minister with warning of 'catastrophic consequences' | 3 killed, several injured in shooting incident in Sweden's Uppsala | BREAKING: PM Modi gives 'full freedom' to forces to avenge Pahalgam terror attack | Canada: Indian student Vanshika, who went missing for past few days, found dead
Bharat Biotech-Covaxin
Image tweeted by @IndianEmbassyTR

Regulatory approvals for Covaxin in process in more than 60 countries: Bharat Biotech says amid travel fears

| @indiablooms | May 26, 2021, at 05:44 am

Hyderabad/IBNS: Amid travel fears that students receiving Covaxin may not be allowed in many countries as the vaccine is not listed, Hyderabad-based pharma major Bharat Biotech on Tuesday said regulatory approvals for its indigenously developed Covid-19 vaccine are in process in more than 60 countries including the US, Brazil and Hungary.

The US, Canada, Australia, Ireland and the EU are among those who do not have Covaxin approved on their list of vaccines for now.

Meanwhile, top universities are reportedly allowing those who have received vaccines approved by the countries or World Health Organisation (WHO).

Emergency use authorisations (EUA) have been obtained from 13 countries with more to follow, Bharat Biotech informed.

It has submitted an application to the WHO to get a EUL (Emergency Use Listing) for indigenously developed Covid-19 vaccine Covaxin and regulatory approvals are expected by Jul-Sept 2021.

Most countries recommend vaccinations against COVID-19.

Unvaccinated travellers can travel with negative RT-PCR tests prior to travel, in the absence of any other country-specific travel restrictions.

Covaxin, which has been priced at around $15-20 per dose for the export market, has already received EUA in several countries like Mexico, Philippines, Iran, Paraguay, Guatemala, Nicaragua, Guyana, Venezuela, Botswana, Zimbabwe and Nepal.

On social media platform Twitter, Bharat Biotech Joint Managing Director Suchitra Ella said Covaxin reaches 30 cities within 30-day.

"All our employees are committed, working 24x7 thru lockdowns for the country’s immunization. Some of the employees are still quarantined and off work," she said.

The list of cities that Covaxin has reached through private hospital dispatches that include the metros and Tier-I cities like Bengalore, Delhi, Chennai, Hyderabad, Kolkata, Mumbai and Pune, Ella tweeted.

Dr. Raches Ella, Head-Business Development and International Advocacy of Bharath Biotech, while in a recent virtual conversation with members of FICCI Ladies Organisation (FLO) here, said we will soon ramp up its manufacturing capacity to 700 million doses by the end of this year.

The indigenous Covaxin vaccine is co-developed by Bharat Biotech and ICMR, Dr Raches said the Government placed an advanced purchase order of rupees 1500 crore and this will help our company to increase our risk appetite and that is why we are expanding to Bangalore and Gujarat.

With UNI inputs

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Close menu